how to avoid weight gain after stopping glp 1 Many Patients Maintain Loss a Year Semaglutide and Liraglutide Stopping GLP-1s: Weight Regain and

The resulting weight lossoften 15-20% of body weight with higher doses approved for obesity (Wegovy/Zepbound) and 5-10% with lower doses for diabetes (Ozempic/Mounjaro)can actually improve several cardiovascular risk factors

Mounjaro is approved for type 2 diabetes management in adults and children 10 years and older, and Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea (OSA) in certain adults

Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization

Inhibiting inflammation

As these medications promote weight loss and alter fluid balance, the cardiovascular system may adjust heart rate to maintain adequate cardiac output and tissue perfusion